These actions are clearly not the result of Akt-mTOR inhibition, as the mTOR inhibitor AZD-2014 or CRISPR/Cas9-induced Akt1 KO failed to affect SphK1 activity, JNK and ROS in NSCLC cells. This evidence concerns the gene MAPK8 and non-small cell lung carcinoma.